Should You Block Estrogen on TRT? What the Research Shows
Start testosterone therapy and it won't be long before someone, a forum post, a friend, sometimes a clinic itself, brings up estrogen. The instinct is almost automatic: testosterone is the goal, estrogen is the enemy, and an aromatase inhibitor like anastrozole is the tool to keep it in check. Plenty of men end up on one reflexively, sometimes before a single estradiol level has even been drawn. The actual research on this points somewhere different.
Where Your Estradiol Is Actually Coming From
More than 80% of the estradiol circulating in a man's body comes from testosterone itself, converted by an enzyme called aromatase, concentrated mainly in fat tissue. Raise testosterone and estradiol rises with it. That's not a side effect or a sign something's going wrong. It's the expected, physiologic result of the same hormone doing what it's built to do. Treating that rise as an automatic problem, before checking whether it's actually causing one, is where a lot of unnecessary aromatase inhibitor use starts.
What Estradiol Actually Does in a Man's Body
Estradiol in men isn't a contamination to manage down to zero. It's doing real, necessary work: maintaining bone density, supporting libido and erectile function, regulating fat metabolism, and contributing to cardiovascular and cognitive health. The instinct to crash it treats a hormone your body needs as if it were purely a threat, when the actual physiology says otherwise.
The Study That Actually Separated These Two Hormones
This question, what specifically goes wrong from low testosterone versus low estradiol, used to be genuinely hard to answer, because the two normally move together. A landmark trial solved that by suppressing both hormones in healthy men with a GnRH agonist, then adding back testosterone at different doses, with half the men also given anastrozole to selectively block the conversion to estradiol. That design let researchers isolate which hormone was actually responsible for which outcome (Finkelstein JS et al., New England Journal of Medicine, 2013 — PMID: 24024838).
The results were specific. Testosterone deficiency accounted for the loss of lean mass, muscle size, and strength. Estrogen deficiency was what primarily drove the increase in body fat. And sexual desire and erectile function declined with deficiency of either hormone, not just testosterone. Crashing estradiol while chasing a testosterone number doesn't protect sexual function. In this trial, it was part of what damaged it.
A follow-up study from the same research group, using the same rigorously controlled cohort, looked specifically at bone. Estrogen deficiency, independent of testosterone status, had a dramatic effect on bone turnover and bone mineral density in men (Finkelstein JS et al., Journal of Clinical Investigation, 2016 — PMID: 26901812). Bone loss is a slow, quiet process. It doesn't show up as a symptom you feel this month.
Why the Fear Persists Anyway
Part of this is cultural rather than clinical: estrogen gets coded as "the female hormone," so any amount showing up on a man's labs can read as something going wrong, rather than a normal, necessary part of male physiology at the right level. Real concerns exist too. Genuinely elevated estradiol, especially in men carrying significant excess body fat, where more aromatase-rich tissue means more conversion, can produce real symptoms: breast tenderness or tissue growth, water retention, mood changes. Those are legitimate reasons to evaluate and treat. They're not a reason to suppress estradiol preemptively in a man who isn't experiencing them.
A Familiar Pattern
A patient came in on TRT elsewhere, already on a standing anastrozole prescription, dealing with joint pain, low libido despite a solid testosterone number, and a general sense that something about the protocol wasn't right. Estradiol came back well below the range associated with normal male physiology. The joint pain and libido complaints weren't a sign he needed more testosterone. They tracked with an estradiol level that had been pushed too low. Reducing the anastrozole and letting estradiol settle into a normal physiologic range resolved both complaints over the following weeks.
What Actually Gets Checked
An aromatase inhibitor is worth discussing when there's a genuine, symptomatic elevation, real gynecomastia symptoms, significant water retention, estradiol clearly above the range associated with those symptoms, not as a standing prophylactic alongside every testosterone prescription. Joint pain, low libido, flat mood, or fatigue on an otherwise well-dosed TRT protocol is worth checking estradiol for, since low estradiol produces some of the same complaints patients and clinicians reflexively attribute to low testosterone. A sensitive estradiol assay matters here too, standard immunoassays aren't always reliable at the lower end of the male reference range, which matters a great deal if a low result is going to justify reducing or stopping an aromatase inhibitor.
What a Realistic Timeline Looks Like
If an aromatase inhibitor dose gets adjusted, whether reduced because estradiol was too low or added because it was genuinely too high, most men notice a shift in how they feel within two to four weeks, with bone-related effects being the exception, since bone density changes on a much longer timeline and isn't something you feel directly. This isn't a set-and-forget protocol. Body composition changes, aromatase activity shifts with fat mass, and estradiol needs periodic reassessment alongside testosterone rather than a one-time dose decision.
If you're chasing a low estradiol number because that's what TRT culture says optimization looks like, it's worth checking whether that number is actually costing you something you'd notice if you knew to look for it.
Have you ever felt worse on TRT and assumed it just meant you needed more testosterone?
A free consultation is a good place to start that conversation, no commitment required, just a chance to look at the full picture together.
— Dr. Darrell Wilcox | @wellnessdoc_4everyoung on Instagram
References
Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine. 2013;369(11):1011-1022 — PMID: 24024838.
Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. Journal of Clinical Investigation. 2016;126(3):1114-1125 — PMID: 26901812.
This content is for educational purposes only and does not constitute medical advice. Aromatase inhibitor use, dosing, and monitoring should be individualized and supervised by a physician, and inappropriate use carries real risks including bone density loss. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
